New hope for kids with tough brain cancers: trial tests Immune-Boosting drug
NCT ID NCT04049669
Summary
This study is testing whether adding an immunotherapy drug called indoximod to standard chemotherapy and radiation can better control aggressive brain tumors in children and young adults. It is for patients aged 3 to 21 with certain progressive brain cancers or a newly diagnosed, hard-to-treat brainstem tumor called DIPG. The goal is to see if boosting the body's immune response helps slow tumor growth and improve survival compared to standard treatment alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Augusta University, Georgia Cancer Center
Augusta, Georgia, 30912, United States
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Emory University, Children's Heathcare of Atlanta
Druid Hills, Georgia, 30322, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.